HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.
Canella A, Cordero Nieves H, Sborov DW, Cascione L, Radomska HS, Smith E, Stiff A, Consiglio J, Caserta E, Rizzotto L, Zanesi N, Stefano V, Kaur B, Mo X, Byrd JC, Efebera YA, Hofmeister CC, Pichiorri F.
Canella A, et al.
Oncotarget. 2015 Oct 13;6(31):31134-50. doi: 10.18632/oncotarget.5290.
Oncotarget. 2015.
PMID: 26429859
Free PMC article.